TPB Q3 Sales Up 27% on Modern Oral Surge, But Adjusted EBITDA Falls 41%
TPB sits 22% above its 52-week low of $54.17.
Summary
Turning Point Brands grew Q3 net sales 27.0% to $151.1M on a doubling of Modern Oral sales, but heavy growth spending drove Adjusted EBITDA down 41.3% to $18.4M. Full-year guidance was reaffirmed.
Key Events · Earnings and Guidance · TPB
-
Q3 Net Sales Up 27.0% to $151.1M
Total consolidated net sales rose 27.0% to $151.1M, with the Stoker's segment up 52.0% to $113.8M and Zig-Zag down 15.5% to $37.3M.
-
Modern Oral Doubles, Now Half of Sales
Modern Oral gross sales rose 114.2% to $93.9M and net sales 102.9% to $74.4M, accounting for 49.2% of total company net sales.
-
Profit Squeezed by Growth Spending
SG&A increased 69.1% to $75.3M on Modern Oral sales and marketing investment; Adjusted EBITDA fell 41.3% to $18.4M and diluted EPS came in at $0.19 versus $1.13 a year ago.
-
FY2026 Guidance Reaffirmed
Management reiterated Modern Oral gross sales of $330-$350M, net sales of $260-$270M, and Adjusted EBITDA of $70-$80M for the full year.
Analysis · TPB · Manufacturing
The revenue growth is real and concentrated: Modern Oral net sales more than doubled to $74.4M and now account for 49.2% of the company, while the legacy Zig-Zag segment shrank 15.5%. Profitability is the problem. SG&A jumped 69.1% to $75.3M as TPB pours money into FRE and ALP distribution and brand building, cutting Adjusted EBITDA 41.3% to $18.4M and diluted EPS to $0.19 from $1.13. Management reaffirmed full-year Modern Oral and Adjusted EBITDA guidance of $70-$80M, so the bet is that the spending is front-loaded growth investment rather than a permanent margin reset. With $251.3M of cash and net debt of only $48.7M, the balance sheet can fund the push; the quarter also included $10.0M of buybacks at an average $59.82 per share.
How filings like this one have moved
In the 30 days to Nov 9, 2026, 36.6% of the 2965 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, TPB was trading at $66.00 on NYSE in the Manufacturing sector, with a market capitalization of approximately $1.3B. The 52-week trading range was $54.17 to $146.90. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.